{"id":"nct:NCT07827768","kind":"trial","title":"AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease","authors":["Institute for Molecular Medicine"],"author_count":1,"year":2026,"published":"2026-09-18","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07827768","source_url":"https://clinicaltrials.gov/study/NCT07827768","archive_url":"https://space-kitty.com/papers/nct:NCT07827768","updated":"2026-10-21","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease. Approximately 160 participants will be randomized to receive AV-1959R or placebo and will be followed for 78 weeks. The study will assess safety, immune responses, brain amyloid, and Alzheimer's disease-related biomarkers.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Preclinical Alzheimer's Disease","Alzheimer Disease"],"details":{"acronym":"AREVIA","status":"NOT_YET_RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":160,"sponsor":"Institute for Molecular Medicine","conditions":["Preclinical Alzheimer's Disease","Alzheimer Disease"],"interventions":["BIOLOGICAL: AV-1959R","DRUG: Placebo"],"start_date":"2027-10-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-10-15","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}